Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Thu, 10.10.2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment
Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
New cli [ … ]
Tue, 01.10.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient
Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 1 [ … ]
Tue, 01.10.2024
Heidelberg Pharma AG
Ad hoc announcement
Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014
Heidelberg Pharma AG Announces Updated Guidance
Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted it [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 11.07.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published
Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024
HDP-101 granted Orphan Drug Designation [ … ]
Fri, 21.06.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma reports on the results of the Annual General Meeting 2024
Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday's ordinary virtual Annu [ … ]
Tue, 18.06.2024
Heidelberg Pharma AG
Ad hoc announcement
Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014
Heidelberg Pharma AG Announces Updated Guidance
Ladenburg, Germany, 18 June 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its [ … ]
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]